Carlsmed (CARL) reported a Q2 loss late Thursday of $1.47 per diluted share, narrower than a loss of $1.55 a year earlier.

Three analysts polled by FactSet expected a loss of $0.71.

Revenue for the quarter ended June 30 rose to $12.1 million from $6.1 million a year earlier.

Three analysts surveyed by FactSet expected $12.0 million.

The company said it expects 2025 revenue of $45.5 million to $47.5 million, representing growth of 67% to 75% over 2024. Analysts polled by FactSet expect $45.7 million.